Amit Soman

Sacramento Kings Take Equity Stake in VOKE

The NBA team the Sacramento (Calif.) Kings announced an investment in Santa Clara, Calif.-based VOKE, a virtual-reality innovator and immersive real-time and on-demand media company. The Kings livestreamed its 2015 home opener to select fans who do not have the opportunity to enjoy NBA basketball in-person. In partnership with NBA India, the Kings will be able to share the opening night experience with viewers more than 8,000 miles away in real-time. “By partnering with VOKE, we can share the in-arena excitement in an unprecedented way," said Kings owner and chairman Vivek Ranadivé. VOKE’s media platform utilizes a synchronized multiple point-of-view stereoscopic panoramic camera system that allows fans to be immersed in live action. The technology enables mobile devices, computers and virtual reality headsets to utilize the same feed. “The Sacramento Kings are well-known as a leader in bringing technology breakthroughs to the sports industry," said VOKE co-founder and CEO Sankar Jayaram. "As such, their investment in VOKE is a strong statement."

Attune Technologies raises $10 million

Attune Technologies Pvt. Ltd., a Chennai-based healthcare technology company, has raised $10 million in Series B funding. The company’s platform interfaces with over 1,100 devices such as lab analyzers and ICU machines to absorb labs into a health network. Arvind Kumar, founder and CEO, said, “We are constantly upgrading our technology and innovating new solutions to make healthcare affordable, seamless and efficient for the entire healthcare value chain.” The company is looking at Africa, West Asia and South East Asia as part of its international expansion plans.

Water For Life Launches Water Filter Campaign

Water For Life announced its campaign to raise funds and awareness to support its global clean water initiatives to bring sustainable access to clean water by delivering high-tech water filters to families, schools, orphanages and entire villages. The company has partnered with Sawyer to provide Personal MINI water filters for pledges that provide Family filters to suffering families, through Indiegogo. Water For Life has already achieved its initial goal of $25,000 to deliver 500 filters to Cambodia and is working on securing funds to send filters to Kenya and India as additional goals. The Personal MINI filters available in the campaign can purify up to 100,000 gallons of clean drinking water from any freshwater lake, river or stream, filtering out 99.9 percent of water borne diseases. A single Family filter has the same filter technology as the MINI with the capability of purifying 150 gallons of water per day for up to 10 years.

Eclipse Ventures Leads $7.4 Million Financing of Flex Logix

Mountain View, Calif.-based Flex Logix Technologies Inc., developer of patented FPGA-in-SoC technology, announced it has secured $7.4 million in equity financing. The company’s EFLXTM Arrays enable field programmable gate arrays to be easily embedded into any system-on-chip, allowing key functions to be optimized or customized after the device is completely fabricated. The financing round was led by dedicated hardware fund Eclipse Ventures. “Eclipse Ventures is excited to invest in Flex Logix,” said Shirish Sathaye. “We are impressed with the power of the technology, the rapid development, the proven software tools and the strong customer traction. We see embedded FPGA as a technology that will become pervasive, and look forward to working with Flex Logix to build a great company.” Flex Logix will use the new capital to expand its engineering and sales team, marketing efforts and other strategic initiatives.

EcoMotors Receives New Investment

Allen Park, Mich.-based EcoMotors announced it has secured a lead investor for their series D funding round — Zhongding Power, a subsidiary of China-based Zhongding Group. The amount of the investment is undisclosed. The investment signals a tightening bond between the two companies, as Zhongding Power signed a product development agreement in 2010 and license agreement in 2013 to develop and produce EM’s opoc engine technology in China. “Zhongding is EM’s first customer; it’s a pleasure to now have them as one of our key investors as well,” EM president and CEO Amit Soman said. The existing agreement with EM represents an investment by Zhongding of more than $200 million. The new plant will have a capacity to produce an estimated 100,000 engines per year.

Relcy announces launch of mobile search application

Mountain View, Calif.-based Relcy announced the general availability of its iOS app. Relcy takes a mobile-centric approach to index, link and rank content across apps and the Web. The search is powered by its expansive knowledge graph, a proprietary indexing technology built from the ground up. Relcy’s knowledge graph maps hundreds of millions of entities, creating an interconnected web of entities, attributes and actions associated with relevant apps. As a result, Relcy will make inferences and add contextual data to provide an even more holistic search result. “Apps have been siloed for too long,” said CEO Rohit Satapathy. “Relcy is here to change that.”

TARIS Biomedical Raises $32 Million

Lexington, Mass.-based TARIS Biomedical LLC, a company using proprietary delivery technology and deep expertise in bladder biology to develop novel treatments for urologic diseases, announced it has relaunched with a $32 million financing led by Flagship Ventures. Last year, the company sold its lead clinical program to Allergan Inc. “The sale to Allergan of our clinical-stage treatment for interstitial cystitis in 2014 was an important validation of our revolutionary approach to treating bladder diseases,” said president and CEO Purnanand Sarma. “Since then we have been working hard to build a high value therapeutically-focused urology company on this foundation. This new funding will enable us to launch multiple clinical trials over the next 12 months and further expand our team.” TARIS’ drug-device combination approach localizes drug treatment to the bladder and enables continuous drug exposure over weeks to months, with the potential to markedly increase efficacy and minimize systemic side effects. The funds also have allowed TARIS to expand its management team and board of directors.

(0) comments

Welcome to the discussion.

Keep it Clean. Please avoid obscene, vulgar, lewd, racist or sexually-oriented language.
Don't Threaten. Threats of harming another person will not be tolerated.
Be Truthful. Don't knowingly lie about anyone or anything.
Be Nice. No racism, sexism or any sort of -ism that is degrading to another person.
Be Proactive. Use the 'Report' link on each comment to let us know of abusive posts.
Share with Us. We'd love to hear eyewitness accounts, the history behind an article.